Pablo Garcia-Pavia

List of Publications by Year
in descending order

155 papers	8,371 citations	44069 48 h-index	53230 85 g-index
169 all docs	169 docs citations	169 times ranked	8924 citing authors

#	Article	IF	Citations
1	Cardiac Transplantation in Danon Disease. Journal of Cardiac Failure, 2022, 28, 664-669.	1.7	5
2	Critical Comparison of Documents FromÂScientific Societies on CardiacÂAmyloidosis. Journal of the American College of Cardiology, 2022, 79, 1288-1303.	2.8	35
3	Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator. European Heart Journal, 2022, 43, 3053-3067.	2.2	41
4	Combination of late gadolinium enhancement and genotype improves prediction of prognosis in nonâ€ischaemic dilated cardiomyopathy. European Journal of Heart Failure, 2022, 24, 1183-1196.	7.1	13
5	Endomyocardial biopsy-confirmed myocarditis and inflammatory cardiomyopathy: clinical profile and prognosis. Revista Espanola De Cardiologia (English Ed), 2022, , .	0.6	1
6	Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Cardiology and Therapy, 2022, 11, 393-405.	2.6	7
7	Systemic embolism in amyloid transthyretin cardiomyopathy. European Journal of Heart Failure, 2022, 24, 1387-1396.	7.1	23
8	Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center. Revista Espanola De Cardiologia (English Ed), 2021, 74, 149-158.	0.6	10
9	Phenotypic clustering of dilated cardiomyopathy patients highlights important pathophysiological differences. European Heart Journal, 2021, 42, 162-174.	2.2	62
10	Efficacy and safety of tafamidis doses in the <scp>Tafamidis in Transthyretin Cardiomyopathy Clinical Trial</scp> (<scp>ATTRâ€ACT</scp>) and longâ€term extension study. European Journal of Heart Failure, 2021, 23, 277-285.	7.1	103
11	Screening of Fabry Disease in Patients with Chest Pain Without Obstructive Coronary Artery Disease. Journal of Cardiovascular Translational Research, 2021, 14, 948-950.	2.4	2
12	Transthyretin amyloid cardiomyopathy. Medicina ClÃ¬nica (English Edition), 2021, 156, 126-134.	0.2	6
13	Are 18F-fluorodeoxyglucose positron emission tomography results reliable in patients with ascending aortic grafts? A prospective study in non-infected patients. European Journal of Cardio-thoracic Surgery, 2021, 60, 148-154.	1.4	6
14	Perfil clÃ¬nico y evoluciÃ³n de la amiloidosis cardiaca en un centro espaÃ±ol de referencia. Revista Espanola De Cardiologia, 2021, 74, 149-158.	1.2	33
15	Amiloidosis cardÃaca por transtiretina. Medicina ClÃ¬nica, 2021, 156, 126-134.	0.6	22
16	Crystallographic Structures of Titin Immunoglobulin-Like I21 Domains Involved in Dilated Cardiomyopathy. Biophysical Journal, 2021, 120, 252a.	0.5	0
17	Predictores de riesgo en una cohorte espaÃ±ola con cardiolaminopatÃas. Registro REDLAMINA. Revista Espanola De Cardiologia, 2021, 74, 216-224.	1.2	19
18	Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2021, 42, 1554-1568.	2.2	434

#	Article	IF	Citations
19	Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology <scp>W</scp>orking <scp>G</scp>roup on <scp>M</scp>yocardial and <scp>P</scp>ericardial <scp>D</scp>iseases. European Journal of Heart Failure, 2021, 23, 512-526.	7.1	153
20	Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. European Journal of Heart Failure, 2021, 23, 895-905.	7.1	57
21	A simple core dataset and disease severity score for hereditary transthyretin (ATTRv) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 189-198.	3.0	12
22	Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 1127-1133.	1.4	3
23	Prevalence and clinical outcomes of dystrophinâ€associated dilated cardiomyopathy without severe skeletal myopathy. European Journal of Heart Failure, 2021, 23, 1276-1286.	7.1	14
24	Nanomechanical Phenotypes in Cardiac Myosin-Binding Protein C Mutants That Cause Hypertrophic Cardiomyopathy. ACS Nano, 2021, 15, 10203-10216.	14.6	16
25	Apical myectomy in patients with apical hypertrophic cardiomyopathy and advanced heart failure. Revista Espanola De Cardiologia (English Ed), 2021, 74, 554-555.	0.6	0
26	A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey. Neurology and Therapy, 2021, 10, 833-845.	3.2	5
27	Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy. European Heart Journal, 2021, 42, 3063-3073.	2.2	51
28	Association of Left Ventricular Systolic Dysfunction Among Carriers of Truncating Variants in Filamin C With Frequent Ventricular Arrhythmia and End-stage Heart Failure. JAMA Cardiology, 2021, 6, 891.	6.1	36
29	Clinical Risk Prediction in Patients With Left Ventricular MyocardialÂNoncompaction. Journal of the American College of Cardiology, 2021, 78, 643-662.	2.8	40
30	Early Preventive Treatment With Enalapril Improves Cardiac Function and Delays Mortality in Mice With Arrhythmogenic Right Ventricular Cardiomyopathy Type 5. Circulation: Heart Failure, 2021, 14, e007616.	3.9	3
31	The SRSF4â€“GAS5-Glucocorticoid Receptor Axis Regulates Ventricular Hypertrophy. Circulation Research, 2021, 129, 669-683.	4.5	11
32	Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis. JACC: Heart Failure, 2021, 9, 736-746.	4.1	26
33	Association of Genetic Variants With Outcomes in Patients With Nonischemic Dilated Cardiomyopathy. Journal of the American College of Cardiology, 2021, 78, 1682-1699.	2.8	55
34	Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey. JACC: CardioOncology, 2021, 3, 537-546.	4.0	21
35	Multiparametric Echocardiography Scores for the Diagnosis of CardiacÂAmyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 909-920.	5.3	136
36	Predicted pathogenic mutations in STAP1 are not associated with clinically defined familial hypercholesterolemia. Atherosclerosis, 2020, 292, 143-151.	0.8	21

#	Article	IF	Citations
37	Mortality Among Referral Patients With Hypertrophic Cardiomyopathy vs the General European Population. JAMA Cardiology, 2020, 5, 73.	6.1	69
38	Clinical Phenotypes and Prognosis of Dilated Cardiomyopathy Caused by Truncating Variants in the TTN Gene. Circulation: Heart Failure, 2020, 13, e006832.	3.9	75
39	Saw-Tooth Cardiomyopathy. JACC: Case Reports, 2020, 2, 1210-1211.	0.6	3
40	Identification of a peripheral blood gene signature predicting aortic valve calcification. Physiological Genomics, 2020, 52, 563-574.	2.3	11
41	Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2020, 396, 759-769.	13.7	481
42	Clinical Profile of Cardiac Involvement in Danon Disease. Circulation Genomic and Precision Medicine, 2020, 13, e003117.	3.6	29
43	Clinical Features and Natural History of PRKAG2 Variant Cardiac Glycogenosis. Journal of the American College of Cardiology, 2020, 76, 186-197.	2.8	45
44	Clinical characteristics and determinants of the phenotype in TMEM43 arrhythmogenic right ventricular cardiomyopathy type 5. Heart Rhythm, 2020, 17, 945-954.	0.7	28
45	Temporal Trends of Wild-type Attr Amyloidosis in the Transthyretin Amyloidosis Outcomes Survey. Journal of Cardiac Failure, 2020, 26, S82.	1.7	2
46	Prevalence, clinical profile and prognostic implications of interatrial block in patients admitted for heart failure. REC: CardioClinics, 2020, 55, 155-164.	0.1	0
47	Usefulness of natriuresis to predict in-hospital diuretic resistance. American Journal of Cardiovascular Disease, 2020, 10, 350-355.	0.5	3
48	Clinical Findings and Prognosis of Danon Disease. An Analysis of the Spanish Multicenter Danon Registry. Revista Espanola De Cardiologia (English Ed), 2019, 72, 479-486.	0.6	9
49	CaracterÃsticas clÃnicas y pronÃ³stico de la enfermedad de Danon. AnÃ¡lisis del registro multicÃ©ntrico espaÃ±ol. Revista Espanola De Cardiologia, 2019, 72, 479-486.	1.2	11
50	Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids). JAMA Cardiology, 2019, 4, 918.	6.1	147
51	Negative screening of Fabry disease in patients with conduction disorders requiring a pacemaker. Orphanet Journal of Rare Diseases, 2019, 14, 170.	2.7	6
52	Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC: Heart Failure, 2019, 7, 709-716.	4.1	188
53	Severe Cardiac Dysfunction and Death Caused by Arrhythmogenic Right Ventricular Cardiomyopathy Type 5 Are Improved by Inhibition of Glycogen Synthase Kinase-3Î². Circulation, 2019, 140, 1188-1204.	1.6	62
54	Efficacy and Safety of Tafamidis Doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT). Journal of Cardiac Failure, 2019, 25, S77-S78.	1.7	1

#	Article	IF	Citations
55	POT1 and Damage Response Malfunction Trigger Acquisition of Somatic Activating Mutations in the VEGF Pathway in Cardiac Angiosarcomas. Journal of the American Heart Association, 2019, 8, e012875.	3.7	8
56	Prevalence of Cardiac Amyloidosis in Patients with Carpal Tunnel Syndrome. Journal of Cardiovascular Translational Research, 2019, 12, 507-513.	2.4	33
57	Prevalence of cardiac amyloidosis among elderly patients with systolic heart failure or conduction disorders. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 156-163.	3.0	33
58	Calmodulin mutations and life-threatening cardiac arrhythmias: insights from the International Calmodulinopathy Registry. European Heart Journal, 2019, 40, 2964-2975.	2.2	116
59	Loss of SRSF3 in Cardiomyocytes Leads to Decapping of Contraction-Related mRNAs and Severe Systolic Dysfunction. Circulation Research, 2019, 125, 170-183.	4.5	41
60	Genetic Variants Associated With Cancer Therapyâ€“Induced Cardiomyopathy. Circulation, 2019, 140, 31-41.	1.6	195
61	High Prevalence of Intracardiac Thrombi in Cardiac Amyloidosis. Journal of the American College of Cardiology, 2019, 73, 1733-1734.	2.8	65
62	Estrategias en congestiÃ³n refractaria: efectos del suero salino hipertÃ³nico en insuficiencia cardiaca aguda. REC: CardioClinics, 2019, 54, 55-57.	0.1	2
63	Association of Sleep Duration and Quality With Subclinical Atherosclerosis. Journal of the American College of Cardiology, 2019, 73, 134-144.	2.8	145
64	Role of copy number variants in sudden cardiac death and related diseases: genetic analysis and translation into clinical practice. European Journal of Human Genetics, 2018, 26, 1014-1025.	2.8	26
65	Prognostic Impact and Predictors of Ejection Fraction Recovery in Patients With Alcoholic Cardiomyopathy. Revista Espanola De Cardiologia (English Ed), 2018, 71, 612-619.	0.6	9
66	Activation of Serine One-Carbon Metabolism by Calcineurin AÎ²1 Reduces Myocardial Hypertrophy and Improves Ventricular Function. Journal of the American College of Cardiology, 2018, 71, 654-667.	2.8	45
67	The Cardiomyopathy Registry of the EUREObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. European Heart Journal, 2018, 39, 1784-1793.	2.2	94
68	The p.Arg118Cys Variant in the GLA Gene Does Not Cause Fabry Disease. More Evidence. Revista Espanola De Cardiologia (English Ed), 2018, 71, 871-873.	0.6	1
69	Role of echocardiography in the diagnosis and management of hypertrophic cardiomyopathy. Heart, 2018, 104, 261-273.	2.9	10
70	International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM). Circulation, 2018, 137, 1015-1023.	1.6	149
71	Formin Homology 2 Domain Containing 3 (FHOD3) Is a Genetic Basis for Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2018, 72, 2457-2467.	2.8	59
72	Dilated Cardiomyopathy DueÂtoÂBLC2-Associated AthanogeneÂ3Â(BAG3)ÂMutations. Journal of the American College of Cardiology, 2018, 72, 2471-2481.	2.8	93

#	Article	IF	Citations
73	Genetic Etiology for Alcohol-Induced Cardiac Toxicity. Journal of the American College of Cardiology, 2018, 71, 2293-2302.	2.8	182
74	Testosterone Replacement Therapy in Deficient Patients With Chronic Heart Failure. Journal of Cardiovascular Pharmacology and Therapeutics, 2018, 23, 543-550.	2.0	16
75	Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population. International Journal of Cardiology, 2018, 270, 192-196.	1.7	69
76	Infective Endocarditis in Patients With Bicuspid Aortic Valve or MitralÂValveÂProlapse. Journal of the American College of Cardiology, 2018, 71, 2731-2740.	2.8	65
77	Usefulness of Genetic Testing in Hypertrophic Cardiomyopathy: an Analysis Using Real-World Data. Journal of Cardiovascular Translational Research, 2017, 10, 35-46.	2.4	10
78	Time delays in the diagnosis and treatment of Fabry disease. International Journal of Clinical Practice, 2017, 71, e12914.	1.7	62
79	Prognostic factors of infective endocarditis in patients on hemodialysis: A case series from a National Multicenter Registry. International Journal of Cardiology, 2017, 241, 295-301.	1.7	13
80	Lung ultrasound as a translational approach for non-invasive assessment of heart failure with reduced or preserved ejection fraction in mice. Cardiovascular Research, 2017, 113, 1113-1123.	3.8	19
81	Psychiatric and cognitive characteristics of individuals with Danon disease (LAMP2 gene) Tj ETQq1 1 0.784314 rgBT /Overlock	1.2	22
82	Lafora Disease Is an Inherited Metabolic Cardiomyopathy. Journal of the American College of Cardiology, 2017, 69, 3007-3009.	2.8	6
83	Nanomechanical Phenotypes in Hypertrophic Cardiomyopathy caused by Missense Mutations in Cardiac Myosin-Binding Protein C. Biophysical Journal, 2017, 112, 164a-165a.	0.5	0
84	Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. European Heart Journal, 2017, 38, 1895-1904.	2.2	258
85	Myocardial Extracellular Volume Is Not Associated With Malignant Ventricular Arrhythmias in High-risk Hypertrophic Cardiomyopathy. Revista Espanola De Cardiologia (English Ed), 2017, 70, 933-940.	0.6	2
86	Genetically Confirmed Familial Hypercholesterolemia in Patients With Acute Coronary Syndrome. Journal of the American College of Cardiology, 2017, 70, 1732-1740.	2.8	111
87	The wide spectrum of POT1 gene variants correlates with multiple cancer types. European Journal of Human Genetics, 2017, 25, 1278-1281.	2.8	66
88	Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis. Progress and Hope. Revista Espanola De Cardiologia (English Ed), 2017, 70, 991-1004.	0.6	43
89	DiagnÃ³stico y tratamiento de la amiloidosis cardiaca por transtiretina. Progreso y esperanza. Revista Espanola De Cardiologia, 2017, 70, 991-1004.	1.2	79
90	Systolic Dysfunction in Infarcted Mice Does Not Necessarily Lead to Heart Failure: Need to Refine Preclinical Models. Journal of Cardiovascular Translational Research, 2017, 10, 499-501.	2.4	2

#	Article	IF	Citations
91	Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation. International Journal of Cardiology, 2017, 248, 232-238.	1.7	41
92	Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. European Heart Journal, 2017, 38, 2649-2662.	2.2	163
93	Animal models of arrhythmogenic right ventricular cardiomyopathy: what have we learned and where do we go? Insight for therapeutics. Basic Research in Cardiology, 2017, 112, 50.	5.9	20
94	Alternative Splicing of NOX4 in the Failing Human Heart. Frontiers in Physiology, 2017, 8, 935.	2.8	32
95	Rationale and design of a multicentre, prospective, randomised, controlled clinical trial to evaluate the efficacy of the adipose graft transposition procedure in patients with a myocardial scar: the AGTP II trial. BMJ Open, 2017, 7, e017187.	1.9	9
96	Additional value of screening for minor genes and copy number variants in hypertrophic cardiomyopathy. PLoS ONE, 2017, 12, e0181465.	2.5	32
97	The Coronary Circulation in Cardiomyopathies and Cardiac Allografts. , 2017, , 119-135.		0
98	Reversible dilated cardiomyopathy: into the thaumaturgy of the heart - Part 2. Neurology International, 2016, 6, .	0.5	0
99	Analysis of diagnostic and therapeutic strategies in advanced cardiac light-chain amyloidosis. Journal of Heart and Lung Transplantation, 2016, 35, 995-1002.	0.6	19
100	Extracellular Volume Detects Amyloidotic Cardiomyopathy and Correlates With Neurological Impairment in Transthyretin-familial Amyloidosis. Revista Espanola De Cardiologia (English Ed), 2016, 69, 923-930.	0.6	6
101	Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies. Journal of the American College of Cardiology, 2016, 68, 2440-2451.	2.8	340
102	The Calcineurin Variant CnAÎ²1 Controls Mouse Embryonic Stem Cell Differentiation by Directing mTORC2 Membrane Localization and Activation. Cell Chemical Biology, 2016, 23, 1372-1382.	5.2	30
103	Infective endocarditis in hypertrophic cardiomyopathy. Medicine (United States), 2016, 95, e4008.	1.0	15
104	Endocarditis in patients with ascending aortic prosthetic graft: a case series from a national multicentre registry. European Journal of Cardio-thoracic Surgery, 2016, 50, 1149-1157.	1.4	12
105	Idiopathic Restrictive Cardiomyopathy IsÂPrimarily a GeneticÂDisease. Journal of the American College of Cardiology, 2016, 67, 3021-3023.	2.8	59
106	Gene network and familial analyses uncover a gene network involving Tbx5/Osr1/Pcsk6 interaction in the second heart field for atrial septation. Human Molecular Genetics, 2016, 25, 1140-1151.	2.9	31
107	Plan of Action for Inherited Cardiovascular Diseases: Synthesis of Recommendations and Action Algorithms. Revista Espanola De Cardiologia (English Ed), 2016, 69, 300-309.	0.6	14
108	Genetic basis of familial dilated cardiomyopathy patients undergoing heart transplantation. Journal of Heart and Lung Transplantation, 2016, 35, 625-635.	0.6	60

#	Article	IF	Citations
109	Hypertrophic remodelling in cardiac regulatory myosin light chain (MYL2) founder mutation carriers. European Heart Journal, 2016, 37, 1815-1822.	2.2	63
110	Aortic composite tube valve graft infection due to Streptococcus pneumoniae. Journal of Nuclear Cardiology, 2016, 23, 168-169.	2.1	1
111	Response to ECG, May 2015. Revista Espanola De Cardiologia (English Ed), 2015, 68, 530.	0.6	0
112	Recommendations regarding diagnosis and treatment of transthyretin familial amyloid polyneuropathy. Medicina ClÃnica (English Edition), 2015, 145, 211-217.	0.2	1
113	Prediction of thromboâ€embolic risk in patients with hypertrophic cardiomyopathy (<scp>HCM</scp>) Tj ETQq1 1 0.784314 rgBT /Ov	7.1	114
114	Natural History and Prognostic Factors in Alcoholic Cardiomyopathy. JACC: Heart Failure, 2015, 3, 78-86.	4.1	78
115	MiocardiopatÃas mitocondriales asociadas a la mutaciÃ³n m.3243A>G en el gen MT-TL1: dos caras de la misma moneda. Revista Espanola De Cardiologia, 2015, 68, 153-155.	1.2	2
116	Mitochondrial Cardiomyopathies Associated With the m.3243A>G Mutation in the MT-TL1 Gene: Two Sides of the Same Coin. Revista Espanola De Cardiologia (English Ed), 2015, 68, 153-155.	0.6	0
117	Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. European Heart Journal, 2015, 36, 2585-2594.	2.2	789
118	Adverse clinical course and poor prognosis of hypertrophic cardiomyopathy due to mutations in FHL1. International Journal of Cardiology, 2015, 191, 194-197.	1.7	5
119	Malignant ventricular arrhythmias in alcoholic cardiomyopathy. International Journal of Cardiology, 2015, 199, 99-105.	1.7	25
120	Respuesta al ECG de mayo de 2015. Revista Espanola De Cardiologia, 2015, 68, 530.	1.2	0
121	ECG de mayo de 2015. Revista Espanola De Cardiologia, 2015, 68, 439.	1.2	0
122	ECG, May 2015. Revista Espanola De Cardiologia (English Ed), 2015, 68, 439.	0.6	0
123	Endophthalmitis and a Heart Murmur. Revista Espanola De Cardiologia (English Ed), 2015, 68, 804.	0.6	0
124	Familial Paralysis of the Atrium Due to a Mutation in SCN5A. Revista Espanola De Cardiologia (English) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.6	0
125	Stop-Gain Mutations in PKP2 Are Associated with a Later Age of Onset of Arrhythmogenic Right Ventricular Cardiomyopathy. PLoS ONE, 2014, 9, e100560.	2.5	22
126	Alcoholic cardiomyopathy. World Journal of Cardiology, 2014, 6, 771.	1.5	116

#	Article	IF	Citations
127	Induction of the calcineurin variant CnAÎ²1 after myocardial infarction reduces post-infarction ventricular remodelling by promoting infarct vascularization. Cardiovascular Research, 2014, 102, 396-406.	3.8	24
128	AplicaciÃ³n prÃ¡ctica de la genÃ©tica en el manejo de las miocardiopatÃas. Cardiocore, 2014, 49, 52-58.	0.0	3
129	Gonococcal endocarditis: a case report and review of the literature. Infection, 2014, 42, 425-428.	4.7	19
130	Left Ventricular Noncompaction. Journal of the American College of Cardiology, 2014, 64, 1981-1983.	2.8	34
131	Genetics in dilated cardiomyopathy. Biomarkers in Medicine, 2013, 7, 517-533.	1.4	42
132	The Alternative Heart: Impact of Alternative Splicing in Heart Disease. Journal of Cardiovascular Translational Research, 2013, 6, 945-955.	2.4	76
133	Heart failure entails significant changes in human nucleocytoplasmic transport gene expression. International Journal of Cardiology, 2013, 168, 2837-2843.	1.7	23
134	Utilidad del anÃ¡lisis genÃ©tico de la miocardiopatÃa hipertrÃ³fica en la prÃ¡ctica real. Revista Espanola De Cardiologia, 2013, 66, 746-747.	1.2	18
135	Usefulness of Genetic Testing for Hypertrophic Cardiomyopathy in Real-world Practice. Revista Espanola De Cardiologia (English Ed), 2013, 66, 746-747.	0.6	3
136	Mutations in the NOTCH pathway regulator MIB1 cause left ventricular noncompaction cardiomyopathy. Nature Medicine, 2013, 19, 193-201.	30.7	296
137	Genetics of arrhythmogenic right ventricular cardiomyopathy. Journal of Medical Genetics, 2013, 50, 280-289.	3.2	56
138	Differential Gene Expression of Cardiac Ion Channels in Human Dilated Cardiomyopathy. PLoS ONE, 2013, 8, e79792.	2.5	64
139	Mitochondrial haplogroups associated with end-stage heart failure and coronary allograft vasculopathy in heart transplant patients. European Heart Journal, 2012, 33, 346-353.	2.2	22
140	Comments on the ESC Guidelines on the Management of Cardiovascular Diseases During Pregnancy. A Critical Vision of Spanish Cardiology. Revista Espanola De Cardiologia (English Ed), 2012, 65, 113-118.	0.6	2
141	Role of Cardiac Scintigraphy With 99mTc-DPD in the Differentiation of Cardiac Amyloidosis Subtype. Revista Espanola De Cardiologia (English Ed), 2012, 65, 440-446.	0.6	19
142	Papel de la gammagrafÃa cardiaca con 99mTc-DPD en la discriminaciÃ³n del subtipo de amiloidosis cardiaca. Revista Espanola De Cardiologia, 2012, 65, 440-446.	1.2	54
143	Mitochondrial tRNA valine as a recurrent target for mutations involved in mitochondrial cardiomyopathies. Mitochondrion, 2012, 12, 357-362.	3.4	15
144	No clinically significant valvular regurgitation in longâ€term cabergoline treatment for prolactinoma. Clinical Endocrinology, 2012, 77, 275-280.	2.4	33

#	Article	IF	Citations
145	Genetic basis of endâ€stage hypertrophic cardiomyopathy. European Journal of Heart Failure, 2011, 13, 1193-1201.	7.1	57
146	Familial Approach in Hereditary Transthyretin Cardiac Amyloidosis. Revista Espanola De Cardiologia (English Ed), 2011, 64, 523-526.	0.6	1
147	Amyloidosis. Also a Heart Disease. Revista Espanola De Cardiologia (English Ed), 2011, 64, 797-808.	0.6	1
148	Familial Evaluation in Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation, 2011, 123, 2701-2709.	1.6	226
149	Desmosomal protein gene mutations in patients with idiopathic dilated cardiomyopathy undergoing cardiac transplantation: a clinicopathological study. Heart, 2011, 97, 1744-1752.	2.9	82
150	Endovascular Treatment of Long-Term Complications Following Surgical Repair of Aortic Coarctation. Revista Espanola De Cardiologia (English Ed), 2010, 63, 473-477.	0.6	1
151	Tratamiento endovascular de complicaciones tardÃas tras la reparaciÃ³n quirÃºrgica de la coartaciÃ³n aÃ³rtica. Revista Espanola De Cardiologia, 2010, 63, 473-477.	1.2	2
152	Assessment of Microcirculatory Remodeling With Intracoronary Flow Velocity and Pressure Measurements. Circulation, 2009, 120, 1561-1568.	1.6	83
153	Late-onset angioedema due to an angiotensin-converting enzyme inhibitor. Canadian Journal of Cardiology, 2007, 23, 315-316.	1.7	6
154	Effect of shear stress on plaque rupture. Canadian Journal of Cardiology, 2007, 23, 396.	1.7	2
155	Characterization of the MHC class I-related MR1 locus in nonhuman primates. Immunogenetics, 2001, 53, 643-648.	2.4	11